Obesity
Conditions
Interventions
This is a two-arm randomized controlled clinical study. Participants will be distributed into groups using a method based on probability in a computer-generated random sequence, with stratified random
H01.158.273.180.350.349
G07.203.650.240
Sponsors
Universidade Federal de Goiás
Universidade Federal de Goiás
Eligibility
Age
20 Years to 59 Years
Inclusion criteria
Inclusion criteria: Volunteers of both sexes; age between 20 and 59 years
Exclusion criteria
Exclusion criteria: Drug users; vitamin and or mineral supplementation; menopausal women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to identify that a nutritional intervention using a system based on genotypic and phenotypic knowledge is more effective than a conventional diet. This difference will be observed by adherence to the diet, measured by self-reported food intake using a 24-hour recall (3 days a week, 2 weekdays and 1 weekend day), from baseline to week 12 and week 24 dietary intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to identify that a nutritional intervention using a system based on genotypic and phenotypic knowledge is more effective than a conventional diet in reducing cardiometabolic risk factors: 1)Lipid Profile Change [Period: Baseline, Week 12, Week 24], measurements of Total Cholesterol, LDL Cholesterol, VLDL Cholesterol, HDL Cholesterol, and Triglycerides will be evaluated to assess lipid profile change. 2)Change in body composition [Period: Baseline, week 12, week 24], body fat percentage and muscle mass percentage will be assessed to assess change in body composition. Measurements will be evaluated using Dual Energy Radiological Absorptiometry. The body composition percentage will be considered high when greater than or equal to 32% for women and greater than or equal to 25% for men. 3)Body weight change [Period: Baseline, week 12, week 24] body weight measurement (kg) will be assessed to assess body weight change. 4)Change in anthropometric measurements [Period: Baseline, Week 12, Week 24], waist circumference (cm) and hip circumference (cm) will be assessed to assess change in anthropometric measurements. 5)Change in Body Mass Index (BMI) [Period: Baseline, week 12, week 24], Body Mass Index (BMI) will be assessed to identify overweight and obesity. 6)Tumor necrosis factor-alpha (TNF-alpha) and interleukin levels [Period: Baseline, week 12, week 24], change in TNF-alpha (pg/ml) and determination of serum Interleukin (IL) levels 6, IL1, IL10 (pg/ml) will be evaluated as inflammation markers. 7)Glycemic and insulin changes [Period: Baseline, week 12, week 24], measuring your levels will determine changes in this parameter. Glycemia (mg/dL). Insulin (uU/mL), insulin resistance (HOMA-IR), beta-cell function (HOMA Beta) | — |
Countries
Brazil
Contacts
Public ContactNara da Silva
Universidade Federal de Goiás
Outcome results
None listed